COMP <GO>
ARWR vs JNJ // PIOTROSKI F-SCORE QUALITY
Arrowhead Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ARWR 4
— JNJ 9
■ METRIC PARITY
LAST: $59.90 (-0.98%) • MKT CAP: $8.54B
piotroski-score
8/9
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARWR VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARWR | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.10% | 25.50% | -14.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 73.8x | 18.5x | +55.30 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 1.84% | 2.97% | -1.13 | JNJ | /fcf-yield <GO> |
| Operating Margin | 11.90% | 34.70% | -22.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -0.20% | 28.50% | -28.70 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 6.00% | +174.00 | ARWR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.60 | 5.59 | +1.01 | ARWR | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.20% | -0.40 | ARWR | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.9 | 60.4 | -19.47 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 1.08 | -0.12 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 23.0x | -5.00 | ARWR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.54B | $662.49B | -$653.95B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARWR REV | JNJ REV | ARWR GROSS % | JNJ GROSS % | ARWR FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $829.4M | $94.19B | 44.0% | 67.9% | $156.9M | $19.70B |
| FY 2024 | $3.6M | $88.82B | 44.0% | 69.1% | -$604.3M | $19.84B |
| FY 2023 | $240.7M | $85.16B | 44.0% | 44.0% | -$164.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARWR // BETA 0.96
JNJ // BETA 1.08